Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data
Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data
MIRA Pharmaceuticals Inc (NASDAQ:MIRA) stock is trading higher on Thursday, with a strong session volume of 47.90 million, according to data from Benzinga Pro.
據Benzinga Pro的數據，納斯達克（NASDAQ：MIRA）的MIRA藥品股票週四交易較高，成交量爲4790萬。
The company announced new insights from additional recently received preclinical study data regarding the mechanism of action and toxicology data for its novel oral ketamine analog, Ketamir-2.
該公司宣佈根據其新近收到的補充臨床前研究數據獲得新的機制和毒性數據方面的新觀點，其新型口服氯胺酮類似物肯他米-2的候選藥品。
Ketamir-2 is MIRA's drug candidate being investigated as a potential treatment for neurological and neuropsychiatric disorders.
肯他米-2是MIRA正在研究作爲治療神經和神經精神紊亂的潛在治療方案的藥物候選。
Related: Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders.
相關：納斯達克股票MIRA藥品的口服氯胺酮類似物在神經精神紊亂方面顯示出潛力。
The new preclinical study results announced are the latest in a string of research developments progressing MIRA's goal of submitting an Investigational New Drug Application (NDA) to the FDA for Ketamir-2 later this year.
新公佈的臨床前研究結果是連續一系列研究發展，推進MIRA今年晚些時候向FDA提交Ketamir-2的新藥申請（NDA）目標的最新進展。
The latest preclinical data reveals that Ketamir-2 is a selective inhibitor of the NMDA receptor of glutamate, the primary excitatory neurotransmitter in the human brain, specifically interacting at the PCP-binding site of the NMDA complex.
最新的臨床前數據顯示，Ketamir-2是人類大腦中主要的興奮性神經遞質穀氨酸（glutamate）的NMDA受體的選擇性抑制劑，特別是在NMDA複合物的PCP結合位點上發生作用。
Ketamir-2 has a 30-50-fold lower affinity to the PCP site than ketamine.
Ketamir-2對PCP位點的親和力是氯胺酮的30-50倍。
The lower affinity is important because compounds may affect neurobehavioral functions at high affinity, potentially leading to side effects such as dissociation and hallucinations.
較低的親和力很重要，因爲化合物在高親和力下可能影響神經行爲功能，潛在地導致偏離和幻覺等副作用。
Unlike traditional ketamine, which also affects several other sites on the NMDA receptor and interacts with opioid receptors, dopamine and serotonin transporters, and various acetylcholine receptors, Ketamir-2 exhibits unique selectivity and does not interact with these additional receptor sites.
與傳統的氯胺酮不同，氯胺酮也影響NMDA受體上的其他幾個結合位點，與阿片受體、多巴胺和血清素轉運體以及各種乙酰膽鹼受體相互作用，而Ketamir-2表現出獨特的選擇性，並不與這些額外的受體位點相互作用。
Recently conducted toxicology studies in rats and dogs have shown no toxicity at very high doses of Ketamir-2.
最近進行的大鼠和狗的毒理學研究顯示，Ketamir-2的很高劑量沒有毒性。
These findings underscore Ketamir-2's favorable safety margin, further supported by its antidepressant and anxiolytic activities observed at oral doses five to tenfold lower than those tested in the toxicology studies.
這些發現強調了Ketamir-2的有利安全保障，進一步支持了其抗抑鬱和抗焦慮的活性，在毒理學研究中測試劑量的五到十倍的口服劑量下觀察到。
The company says that Ketamir-2 could potentially be beneficial in treating conditions like depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD).
該公司表示，Ketamir-2在治療憂鬱症、耐藥性憂鬱症（TRD）和創傷後應激症（PTSD）方面有潛在益處。
Price Action: MIRA stock is up 38.8% at $3.27 at last check Thursday.
MIRA股票週四上漲38.8%，收於3.27美元。
- AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
- 艾伯維公司第二季度收益超出預期，因新型免疫和癌症藥物銷售強勁提高了年度利潤。